A5018134899- Cardiovascular Disease and Adiposity
- SARS-CoV-2 and COVID-19 Research
- Cerebrovascular and Carotid Artery Diseases
- Cardiac Imaging and Diagnostics
- COVID-19 Clinical Research Studies
- Cardiovascular Health and Disease Prevention
- Atherosclerosis and Cardiovascular Diseases
- Infective Endocarditis Diagnosis and Management
- COVID-19 Impact on Reproduction
- Respiratory viral infections research
- Aortic aneurysm repair treatments
- Vaccine Coverage and Hesitancy
- Lipid metabolism and disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lipoproteins and Cardiovascular Health
- Animal Virus Infections Studies
- Cardiac Valve Diseases and Treatments
- Cardiac Health and Mental Health
- Inflammasome and immune disorders
- Cardiomyopathy and Myosin Studies
- SARS-CoV-2 detection and testing
- Immune Response and Inflammation
- Inflammatory Biomarkers in Disease Prognosis
- Vitamin D Research Studies
- Oral microbiology and periodontitis research
Moderna Therapeutics (United States)
2022-2025
Akebia Therapeutics (United States)
2020-2021
Seqirus (United States)
2019
Harvard University
2010-2017
Massachusetts General Hospital
2007-2017
University Medical Center Utrecht
2016
Cornell University
2016
Baptist Hospital of Miami
2011-2014
MGH Institute of Health Professions
2012
Harvard–MIT Division of Health Sciences and Technology
2011
Loss-of-function mutations in ANGPTL3 are associated with beneficial effects on lipid and glucose metabolism reduced risk of coronary artery disease. Vupanorsen (AKCEA-ANGPTL3-L Rx ) is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively inhibits angiopoietin-like 3 (ANGPTL3) protein synthesis.This was a double-blind, placebo-controlled, dose-ranging, Phase 2 study. Patients (N =105) fasting triglycerides >150 mg/dL (>1.7 mmol/L), type...
Abstract Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels patients at high for or established disease. Methods and results A randomized, double-blind, placebo-controlled, dose-ranging study was conducted 114 fasting serum triglycerides...
Background— Several high-risk morphological features (HRM) of plaques, especially in combination, are associated with an increased risk a clinical event. Although plaque inflammation is also atherothrombosis, the relationship between and number HRM not well understood. Methods Results— Thirty-four patients underwent 18 flurodeoxyglucose positron emission tomography (FDG-PET) imaging, carotid atherosclerotic was assessed (target-to-background ratio). Additionally, subset 10 subjects stenosis...
Arterial calcium (Ca) deposition has been identified as an active inflammatory process. We sought to test the hypothesis that local vascular inflammation predisposes subsequent arterial in humans.From a hospital database, we 137 patients (age, 61 ± 13 years; 48.1% men) who underwent serial positron-emission tomography/computed tomography (1-5 years apart). Focal was prospectively determined by measuring 18F-flourodeoxyglucose uptake (using baseline tomography) within predetermined locations...
The objective of this study was to evaluate how different measures adiposity are related both arterial inflammation and the risk subsequent cardiovascular events.We included individuals who underwent (18)F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for oncological evaluation. Subcutaneous adipose tissue (SAT) volume, visceral (VAT) VAT/SAT ratio were determined. Additionally, body mass index, metabolic syndrome, aortic uptake (a measure inflammation)...
The highly transmissible severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant is a global concern. This study assessed the neutralization activity of two-dose regimens mRNA-1273 vaccination against in adults, adolescents and children.Neutralizing was evaluated serum samples from adults (≥18 years) phase 3, Coronavirus Efficacy (COVE) (12-17 TeenCOVE trials following regimen 100 μg children (6-<12 KidCOVE trial administered two doses 50 mRNA-1273. Neutralizing antibody...
Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a noninferior immune response compared with licensed trivalent (aTIV-1; Fluad™) and aTIV-2 containing an alternate B strain, examine aQIV had immunological superiority for the strain absent from aTIV comparators, evaluate reactogenicity safety among adults ≥65 years. In multicenter, double-blind, randomized controlled trial, years were 2:1:1 to vaccination (n = 889), aTIV-1 445), or 444) during 2017-2018 season....
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose 100-µg primary series TeenCOVE trial (NCT04649151) offered booster. Primary objectives included safety inference by establishing noninferiority neutralizing antibody (nAb) responses after compared nAb post-primary among young adults COVE (NCT04470427). Binding (bAb) against variants...
Cell-mediated immunity may provide durable protection against severe COVID-19, including among solid organ transplant recipients (SOTRs). This exploratory analysis in the open-label phase 3b trial evaluated cell-mediated of mRNA-1273 a subset participants (59 kidney and 33 liver SOTRs; 12 immunocompetent participants). In Part A, SOTRs received three 100-µg doses mRNA-1273; two doses. B, an additional dose was offered ≥4 months after primary series. SARS-CoV-2 spike (S) protein-specific...
Longitudinal changes in vaccination-induced immune response remain inadequately characterized adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series, immunogenicity single dose of 50 μg vaccine-naïve
Abstract Background Solid organ transplant recipients (SOTRs) are at high risk for severe COVID-19. Methods This open-label, phase 3b trial evaluated mRNA-1273 in 137 kidney and 77 liver SOTRs 20 immunocompetent participants. In part A, received three 100-µg doses of mRNA-1273; participants 2 doses. B, an additional dose was offered ≥4 months after the primary series. Here, we report interim results. Results well-tolerated SOTRs. Four serious adverse events were considered vaccine related by...
Higher-dose mRNA booster vaccines have not been well studied for transplant recipients. This study evaluated the safety, reactogenicity and immunogenicity of higher dose mRNA-1273 among lung recipients (LTRs). phase 1/2 open-label randomized clinical trial higher-dose vaccination enrolled nineteen adult LTRs into 50 ug (n=8) vs. 100 (n=11) groups before enrollment was terminated due to availability bivalent mRNA-1273.222 vaccine. Local systemic predominantly mild or moderate in severity both...
Abstract Background Increased community COVID-19 cases prompted the clinical evaluation of an mRNA-1273 booster dose (BD) in TeenCOVE adolescent participants (12-17 years) who received a 2-dose primary series. At ≥5 months after 2 (coinciding with omicron wave peak Jan 2022), were offered optional 50-µg BD. Here, we inferred BD effectiveness adolescents by demonstrating non-inferiority (NI) neutralizing antibody (nAb) responses post-BD vs young adults (18-25 post-dose 100-μg series pivotal...
Background : It has been well demonstrated that inflammation is strongly associated with ruptured plaques. Invasive angiographic studies have shown vulnerable plaques tend to be clustered proximally in the coronary arteries. We tested hypotheses patients ACS a higher overall level of their proximal vessels compared stable disease and gradient inflammatory activity seen within vasculature. Methods Twenty-five (mean age 57.9 ± 9.8 years, 72% male) who underwent angiography for chest pain were...